Introduction Following the coronavirus disease pandemic, respiratory mucosal vaccines that
elicit both mucosal and systemic immune responses have garnered increasing attention …

Background The live-attenuated influenza virus vector-based intranasal SARS-CoV-2
vaccine (dNS1-RBD, Pneucolin; Beijing Wantai Biological Pharmacy Enterprise, Beijing …

The COVID-19 pandemic remains a serious public health problem globally. During winter
influenza seasons, more aggressive SARS-CoV-2 infections and fatalities have been …

Immunoglobulin A (IgA) is critical in the immune response against respiratory infections like
COVID-19 and influenza. IgA is one of the five main classes of immunoglobulins or …

Background The pivotal phase 3 efficacy clinical trial has demonstrated that a two-dose
regimen of dNS1-RBD (Beijing Wantai Biological Pharmacy Enterprise, Beijing, China) is …

Klebsiella pneumoniae is the main pathogen of hospital-acquired infections causing acute
pneumonia, which is characterized by drug resistance, virulence and mortality, and for which …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with different
antigenic variants, has posed a significant threat to public health. It is urgent to develop …

Despite multiple research efforts to characterize COVID-19 in humans, there is no clear data
on the specific role of mucosal immunity on COVID-19 disease. Here, we longitudinally …

Coronavirus disease 2019, caused by severe acute respiratory syndrome coronavirus 2
(SARS‐CoV‐2), has affected 700 million people worldwide since its outbreak in 2019. The …

Coronavirus disease 2019 (COVID-19), the global pandemic caused by severe acute
respiratory syndrome 2 virus (SARS-CoV-2) infection, has caused millions of infections and …